

201423026A

厚生労働科学研究費補助金
肝炎等克服緊急対策研究事業

肝疾患患者における肝がん発症に寄与する
宿主遺伝要因の同定・遺伝子機能解析を目指す研究

(H25-肝炎-若手-013)

平成 26 年度 総括研究報告書

研究代表者 西田 奈央

平成 27(2015)年 3 月

***** 目 次 *****

I. 総括研究報告書	
肝疾患患者における肝がん発症に寄与する宿主遺伝要因の同定・遺伝子機能解析を目指す研究（西田奈央）	……………01
II. 研究成果の刊行一覧	……………05
III. 研究成果の刊行物・別刷	……………07

I. 総括研究報告書

厚生労働科学研究費補助金（肝炎等克服緊急対策研究事業）
総括研究報告書（平成 26 年度）

肝疾患患者における肝がん発症に寄与する宿主遺伝要因の同定・
遺伝子機能解析を目指す研究

研究代表者：西田 奈央 国立国際医療研究センター 上級研究員

研究要旨：新たに収集した日本人B型肝炎患者群892名と健常対照群761名を対象としてHLA-DPBIタイピングを実施し、本研究においてこれまでに明らかとなっているHLA-DPBI遺伝子とB型慢性肝炎や肝発がんとの関連がより確かとなることが明らかとなった。加えて、個別のDPBI genotypeでの関連解析を実施したところ、i) 感受性/抵抗性アリルを2つ有する症例で関連が相加的に強くなる、ii) 感受性アリルと抵抗性アリルのヘテロ症例ではどの組み合わせでも抵抗性の関連を示す、iii) 感受性アリルのヘテロ症例、および抵抗性アリルのヘテロ症例はホモ症例よりも有意に関連が強まる、ことが明らかとなった。また、新たに収集したHBV患者群および健常対照群の合計892例について、Affymetrix AXIOM ASIプラットフォームによるゲノムワイドSNPタイピングを実施し、GWASおよびHLA-DPBIアリルでの層別化GWASを実施した。検出した有望な遺伝子領域について、今後、Imputation解析を進める。加えて、ゲノムワイドSNPタイピングデータからHLA Imputationを実施することにより、高い精度で5つのHLA遺伝子（HLA-A, HLA-B, HLA-DRB1, HLA-DQB1, HLA-DPBI）の遺伝子型を推定することが可能となった。2型糖尿病を背景に持つ肝発癌患者を対象として、2型糖尿病発症に関連するSNPについて関連解析を実施したところ、肝発癌に有意な関連を示す新たなSNPを検出した。

A. 研究目的

日本は先進国中で肝がんが最も多い国であり、近年では肝炎ウイルスが原因の肝がん発症だけでなく、HBV、HCV 以外を背景とする肝がん患者が増加している。また、欧米だけでなく日本においても肥満と糖尿病の増加が社会的な問題の一つとなっており、肥満や糖尿病から肝臓がんが誘発されることが裏付けられていることから、糖尿病と肝がんの関わりを明らかにすることを本研究の目的とする。

本研究は2つの最終目標達成を目指す。1つは、「B型肝炎およびC型肝炎由来肝がんの関連遺伝子の同定およびその遺伝子機能の解明」とし、もう1つは「各種肝疾患における2型糖尿病発症の関連遺伝子の同定とその遺伝子機能の解明」とする。

B. 研究方法

研究全体の計画として、肝がん関連遺伝子の同定、および2型糖尿病患者における肝発癌関連遺伝子の同定を目指して、ゲノムワイドSNP解析やNGSを用いたゲノム解析を実施する。NGSを用いたゲノム解析では、100検体程度の肝がん患者を対象として全RNA解析や全ゲノム解析を実施し、癌化に関連する融合遺伝子やゲノム変異、ゲノム構造異常などを探索する（平成25-26年度）。また、肝がん患者群を対象としたGWASでは多くの検体を必要とするため、FFPEサンプルが使用できる状態になった後でゲノムワイドSNP解析を実施する（平成26-27年度、目標症例数：1,000検体）。また、2型糖尿病患者の中で肝細胞癌を有する群、有さない群に分けた関連解析を実施することで、2型糖尿病患者における肝発癌の関連遺伝子の同定を目指す。必要に応じて、疾患感受性遺伝子領域を対象とし

た Target resequencing や全 RNA 解析、全ゲノム解析などを実施し、ゲノム解析データと各検体の詳細な臨床背景を加えて統合的に解析することで、その遺伝子機能の解明を目指す（平成 27 年度）。

（倫理面への配慮）

本研究に関係するすべての研究者はヘルシンキ宣言（平成 20 年 10 月修正）を遵守する。かつ、臨床研究に関する倫理指針（平成 20 年 7 月 31 日全部改正）、およびヒトゲノム・遺伝子解析研究に関する倫理指針（平成 25 年 2 月 8 日全部改正）に則って本研究を実施するものとする。研究遂行者の供与される情報は、個人識別情報を除き供与される。即ち、連結可能匿名化とする。個人情報に関しては、個人情報識別管理者（国府台病院：管理課長、国立国際医療研究センター病院：企画戦略室長）をおき、情報管理には細心の注意をはらう。また、患者個人識別情報と検体との対応表は、独立の鍵が掛かる場所に厳重に保管する。さらに、個人情報の管理をパソコンで行う場合には、当該パソコンをネットに連結することなく単独で使用し、独立の鍵の掛かる場所に厳重に保管する。

C. 研究結果

(1) Affymetrix 社や Illumina 社のゲノムワイド SNP タイピングデータを用いて、StaGen 社と共同で *HLA* 遺伝子の Tagging SNP の選択を行った結果、5 つの *HLA* 遺伝子 (*HLA-A*, *HLA-B*, *HLA-DRB1*, *HLA-DQB1*, *HLA-DPBI*) について 95.2%-99.5% の精度で Imputation が可能となった（論文発表(1)参照）。

(2) 新たに収集した日本人 B 型肝炎患者群 892 名と健常対照群 761 名のゲノム DNA を用いて *HLA-DPBI* タイピングを実施し、*HLA-DPBI* アリルと B 型肝炎慢性化の関連解析を実施した。2014 年に論文報告した結果（Nishida et al. *PLoS One* 2014）と合わせた関連解析を実施したところ（B 型肝炎患者群 1,380 名、健常対照群 1,225 名）、B 型肝炎慢性化に対して抵抗性の関連を示す 3

つの *DPBI* アリル（*DPBI*02:01*、*DPBI*04:01*、*DPBI*04:02*）、および感受性の関連を示す 2 つの *DPBI* アリル（*DPBI*05:01*、*DPBI*09:01*）の関連がより確かとなることが明らかとなった。この成果について、現在論文投稿中である。

(3) 日本人 B 型肝炎患者群 1,380 例および健常対照群 1,225 例について、個別の *HLA-DPBI* 遺伝子型で関連解析を実施したところ、i) 感受性/抵抗性アリルを 2 つ有する症例で関連が相加的に強くなる、ii) 感受性アリルと抵抗性アリルのヘテロ症例ではどの組み合わせでも抵抗性の関連を示す、iii) 感受性アリルのヘテロ症例、および抵抗性アリルのヘテロ症例ではホモ症例よりも有意に関連が強まる、ことが明らかとなった。この成果について、現在論文投稿中である。

(4) 2012 年以降に新たに収集した B 型慢性肝炎患者および健常対照群の合計 892 例について、Affymetrix AXIOM ASI プラットフォームによるゲノムワイド SNP タイピングを実施した。これまでに取得済みのタイピングデータと共に、*HLA-DPBI* アリルでの層別化 GWAS を実施した（HBV 患者群 1,019 例、健常対照群 645 例）。2 つの感受性アリルおよび 3 つの抵抗性アリルの有無で層別化 GWAS を実施したところ、抵抗性アリルを有する症例での層別化 GWAS（B 型慢性肝炎患者群 429 名、健常対照群 403 名）において、有意な関連を示す遺伝子領域を検出した（ $P = 7.04 \times 10^{-8}$ ）。加えて、感受性アリルを有する症例での層別化 GWAS も実施し、 $P < 10^{-5}$ となった SNP を含む遺伝子領域について、東北メディカルメガバンクとの共同研究で Imputation 解析を実施している。Imputation 解析でより有望な SNP が検出された場合には、その SNP を対象として Replication 解析を実施する予定である。

(5) 2 型糖尿病を背景に有する肝発癌患者（ $n = 59$ ）および非肝発癌患者（ $n = 330$ ）について、2 型糖尿病の疾患感受性 SNP として報告された 58SNPs を対象とした関連解析を実施したところ、有意な関連を示す遺伝

子領域を検出した ($P = 0.0009$)。この成果について、現在投稿論文を作成中である。

D. 考察

これまでに取得したゲノムワイド SNP タイピングデータを用いて HLA Imputation (5 つの遺伝子座) を実施することが可能となったことから、*HLA-DPB1* 遺伝子以外の HLA class II 遺伝子 (*DRB1* 遺伝子や *DQB1* 遺伝子) や HLA class I 遺伝子と B 型慢性肝炎や肝発がんとの関連を調べるのが可能となった。

E. 結論

HLA Imputation を実施し、*HLA class II* 遺伝子だけでなく *HLA class I* 遺伝子と B 型慢性肝炎や肝発がんとの関連解析を実施する。

F. 健康危険情報 該当なし

G. 研究発表

1. 論文発表

(1) Seik-Soon Khor, Woosung Yang, Minae Kawashima, Shigeo Kamitsuji, Xiuwen Zheng, **Nao Nishida**, Hiromi Sawai, Hiromi Toyoda, Taku Miyagawa, Makoto Honda, Naoyuki Kamatani, Katsushi Tokunaga, High-accuracy imputation for HLA class I and II genes based on high-resolution SNP data of population-specific references, *Pharmacogenomics J* [Epub ahead of print] 2015

2. 学会発表

(1) **Nao Nishida**, Hiromi Sawai, Kouichi Kashiwase, Masaya Sugiyama, Yoriko Mawatari, Katsushi Tokunaga, Masashi Mizokami, Association of HLA-DPB1 alleles with CHB infection and HBV related HCC in Asia. 62th Annual ASHG Meeting,

San Diego, 2014

(2) **Nao Nishida**, Hiromi Sawai, Koichi Kashiwase, Mutsuhiko Minami, Ken Yamamoto, Takehiko Sasazuki, Masaya Sugiyama, Wai-Kay Seto, Man-Fung Yuen, Yong Poovorawan, Sang Hoon Ahn, Kwang-Hyub Han, Kentaro Matsuura, Yasuhito Tanaka, Masayuki Kurosaki, Yasuhiro Asahina, Namiki Izumi, Jong-Hon Kang, Shuhei Hige, Tatsuya Ide, Kazuhide Yamamoto, Isao Sakaida, Yoshikazu Murawaki, Yoshito Itoh, Akihiro Tamori, Etsuro Orito, Yoichi Hiasa, Masao Honda, Shuichi Kaneko, Eiji Mita, Kazuyuki Suzuki, Keisuke Hino, Eiji Tanaka, Satoshi Mochida, Masaaki Watanabe, Yuichiro Eguchi, Masaaki Korenaga, Minae Kawashima, Katsushi Tokunaga, Masashi Mizokami, Associations of HLA-DPB1 with CHB infection and HBV related HCC in Asia. American Association for the study of Liver Diseases The Liver Meeting 2014, Boston, 2014

(3) **西田奈央**、徳永勝士、溝上雅史、B 型肝炎慢性化および癌化に関連する HLA-DP 遺伝子のアジア人集団における横断的解析 第 50 回 日本肝臓学会、京都、2014 年 6 月 5 日-6 日

(4) **西田奈央**、澤井裕美、杉山真也、馬渡頼子、徳永勝士、溝上雅史、B 型肝炎慢性化および病態進展に関わる HLA-DP アレルの横断的解析 第 50 回 日本肝臓学会総会、赤坂、2014 年 5 月 29 日-30 日

H. 知的所得権の出願・登録状況

1. 特許取得

(1) 発明の名称：B 型肝炎の慢性化の素因の検出方法

発明者：徳永勝士、澤井裕美、溝上雅史、**西田奈央**

出願日：2013 年 8 月 30 日

出願番号：特願 2013-179634

2. 実用新案登録

該当なし

3. その他

該当なし

Ⅱ. 研究成果の刊行一覧

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻・号	ページ	出版年
Seik-Soon Khor, Woosung Yang, Minae Kawashima, Shigeo Kamitsuji, Xiuwen Zheng, Nao Nishida , Hiromi Sawai, Hiromi Toyoda, Taku Miyagawa, Makoto Honda, Naoyuki Kamatani, Katsushi Tokunaga	High-accuracy imputation for HLA class I and II genes based on high-resolution SNP data of population-specific references	<i>Pharmacogenomics J</i>			2015

Ⅲ. 研究成果の刊行物・別刷

ORIGINAL ARTICLE

High-accuracy imputation for *HLA* class I and II genes based on high-resolution SNP data of population-specific referencesS-S Khor¹, W Yang², M Kawashima¹, S Kamitsuji², X Zheng³, N Nishida^{1,4}, H Sawai¹, H Toyoda¹, T Miyagawa¹, M Honda⁵, N Kamatani² and K Tokunaga¹

Statistical imputation of classical human leukocyte antigen (*HLA*) alleles is becoming an indispensable tool for fine-mappings of disease association signals from case–control genome-wide association studies. However, most currently available *HLA* imputation tools are based on European reference populations and are not suitable for direct application to non-European populations. Among the *HLA* imputation tools, The HIBAG R package is a flexible *HLA* imputation tool that is equipped with a wide range of population-based classifiers; moreover, HIBAG R enables individual researchers to build custom classifiers. Here, two data sets, each comprising data from healthy Japanese individuals of difference sample sizes, were used to build custom classifiers. *HLA* imputation accuracy in five *HLA* classes (*HLA-A*, *HLA-B*, *HLA-DRB1*, *HLA-DQB1* and *HLA-DPB1*) increased from the 82.5–98.8% obtained with the original HIBAG references to 95.2–99.5% with our custom classifiers. A call threshold (CT) of 0.4 is recommended for our Japanese classifiers; in contrast, HIBAG references recommend a CT of 0.5. Finally, our classifiers could be used to identify the risk haplotypes for Japanese narcolepsy with cataplexy, *HLA-DRB1*15:01* and *HLA-DQB1*06:02*, with 100% and 99.7% accuracy, respectively; therefore, these classifiers can be used to supplement the current lack of *HLA* genotyping data in widely available genome-wide association study data sets.

The Pharmacogenomics Journal advance online publication, 24 February 2015; doi:10.1038/tpj.2015.4

INTRODUCTION

Human Leukocyte Antigen (*HLA*) represents the primary system, which encodes cell-surface protein that presents the specific antigen peptides for the host immune system. Specific *HLA* proteins have been implicated as the major susceptible factors for adverse drug reactions, transplant/graft rejection and a wide range of autoimmune and infectious diseases. The *HLA*, or major histocompatibility complex (*MHC*), region in humans is located on chromosome 6p21.3 *HLA* loci, and *HLA* proteins are highly polymorphic because of natural selection against a wide range of pathogens.¹ For example, as of October 2014, the IMGT/*HLA* database contained up to 12 000 *HLA* alleles,² and *HLA-B* and *HLA-DRB* were the most polymorphic in *HLA* class I and *HLA* class II genes, with 3693 and 1684 two-field alleles, respectively.

Over the years, different methodologies have been developed for genotyping *HLA* alleles, from classical two-digit serotyping to four-or-more-digit DNA-based typing methods. However, *HLA* genotyping is still notorious for being time consuming and costly for research studies that involve thousands of samples. To overcome these problems, methods for predicting *HLA* genotypes based on single nucleotide polymorphisms (SNPs) have been developed.^{3,4} However, the utility of such prediction methods is limited to specific populations for which a particular prediction system is built. An alternative method uses multiple SNPs in the proximity of *HLA* regions to predict *HLA* genotypes. Leslie *et al.*⁵ developed an *HLA* prediction system based on identity-by-descent model; this system uses multiple SNPs to infer haplotype

information. Using the same statistical algorithm Dilthey *et al.*⁶ developed an integrative software program, *HLA*IMP*, based on SNP data from European populations with a modification of the SNP selection process, which increased the imputation accuracy. A subsequently developed software program, *HLA*IMP:02*,⁷ based on SNP data from multiple populations that can accommodate haplotypic heterogeneity, is also available. Each version of *HLA*IMP* required users to upload the genotype data to a secure, online server; this requirement may exclude certain research groups from using *HLA*IMP*.

SNP2HLA is an *HLA* and amino-acid imputation software program built based on the imputation algorithm used for the software package BEAGLE.⁸ *SNP2HLA* has enabled researchers to interrogate functional coding variants within *HLA* genes that might be causal for certain diseases. Non-synonymous changes within *HLA* genes might cause variations in the binding affinity of the respective *HLA* protein, but the exact underlying mechanisms of how such changes contribute to disease susceptibilities remains unknown.

The HIBAG R package is another tool for *HLA* genotype imputation based on the attribute bagging method.⁹ Attribute bagging maximizes the advantages of bootstrap aggregation and the random variables selection methods to improve accuracy of *HLA* imputation.¹⁰ In brief, ensemble classifiers are built by randomly selecting sets of individuals from a training data set and randomly selecting representative SNP markers from a set of available SNP sets. The ensemble classifiers are then used as

¹Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; ²StaGen Co., Ltd., Statistical Genetics Analysis Division, Tokyo, Japan; ³Department of Biostatistics, University of Washington, Seattle, WA, USA; ⁴The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan and ⁵Sleep Disorders Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. Correspondence: Dr K Tokunaga, Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 1130033, Japan. E-mail: tokunaga@m.u-tokyo.ac.jp

Received 15 August 2014; revised 23 October 2014; accepted 19 December 2014

references for imputation based on an independent research dataset.

HIBAG differs from other *HLA* imputation software because it only assumes minimal Hardy–Weinberg equilibrium, and HIBAG has proven to be robust for populations with complex linkage disequilibrium blocks that deviate from Hardy–Weinberg equilibrium. In contrast with *HLA*IMP* and *HLA*IMP:02*, HIBAG utilizes unphased genotype data directly available from genome-wide association studies SNP panels, shortening the computational phasing steps and eliminating the variation produced by different phasing software packages. HIBAG has, for example, helped to identify novel independent risk *HLA* alleles for Sjögren's syndrome¹¹ and contributed to the confirmation of which *HLA* alleles among those that increase the risk of multiple sclerosis was associated with a decreased risk of schizophrenia.¹²

For *HLA* genotype imputation with a specific population (for example, the Japanese population), it is essential to build custom population training data sets that include rare *HLA* genotypes that are confined to the respective population. Here, we determined the overall *HLA* imputation accuracy attained when using each of two sets of published parameters (HIBAG ASIAN ancestry model or HIBAG multi-ethnic model), as references and validation data sets comprising two groups of healthy Japanese individuals. In addition, functions built into the HIBAG R package were used to generate two custom Japanese population parameter estimates with different sample sizes, and a comprehensive comparison was performed to assess the *HLA* genotype imputation accuracy across three different genotyping platforms and with different training data sets of different sizes. Further assessment of imputation accuracy was carried out using data from the Japanese narcolepsy with cataplexy patient group in which almost 100% of the Japanese patients carried a specific *HLA* haplotype; this genetic uniformity makes narcolepsy with cataplexy a good model for *HLA* imputation assessment.

MATERIALS AND METHODS

Table 1 list the numbers of individuals with four-digit *HLA* genotypes and numbers of unique *HLA* alleles for samples from the following three groups: Tokyo Healthy Control (THC), Japan PGx Data Science Consortium (JPDSC), Japanese narcolepsy with cataplexy and HIBAG published references. Each data set is described below.

THC

THC samples were taken from healthy Japanese individuals residing in the Tokyo area. SNP data from the extended MHC region were extracted from three genotyping platforms: Affymetrix 6.0, Affymetrix Axiom, or Illumina HumanOmni BeadChip 2.5. SNPs that failed quality control criteria (minor allele frequency < 0.05, call rate < 95%, Hardy–Weinberg equilibrium < 0.001) were removed; 1905, 5217 and 6245 SNP markers from the extended MHC region were remained for reference building in the Affymetrix 6.0, Affymetrix Axiom or Illumina HumanOmni 2.5 platforms, respectively.

The Luminex Multi-Analyte Profiling System and WAKFlow *HLA* typing kits (Wakunaga, Hiroshima, Japan) were used to type five *HLA* loci (*HLA-A*, *B*, *DRB1*, *DQB1* and *DPB1*), at four-digit resolution.

JPDSC

SNPs and four-digit *HLA* genotypes were obtained for JPDSC samples, which were collected from healthy Japanese individuals registered with the JPDSC (<http://www.jpds.org/>). Data for SNP markers within the extended MHC regions were extracted from data generated with the Illumina HumanOmni 2.5 platform; after quality control (minor allele frequency < 0.05, call rate < 99%, Hardy–Weinberg equilibrium < 0.0001), 11 145 candidate SNP markers were represented in the final data set.

Luminex Multi-Analyte Profiling System and WAKFlow *HLA* typing kits (Wakunaga) were used to type five *HLA* loci (*HLA-A*, *B*, *C*, *DRB1* and *DPB1*) at four-digit resolution.

Table 1. Numbers of individuals and numbers of unique *HLA* alleles represented in each data set

	HLA					
	A	B	C	DRB1	DQB1	DPB1
<i>Individuals genotyped</i>						
<i>Japanese healthy control</i>						
THC Affymetrix 6.0	415	415	NA	415	415	415
THC Affymetrix Axiom	416	416	NA	416	416	416
THC Illumina	418	418	NA	418	418	418
HumanOmni 2.5						
JPDSC Illumina	2994	2994	2994	2994	NA	2994
HumanOmni 2.5						
<i>Japanese disease group</i>						
Narcolepsy with cataplexy	NA	398	NA	86	398	398
<i>HIBAG reference</i>						
Asian ancestry	606	713	611	696	612	527
Multi-ethnic	2901	3886	2916	3713	2985	2489
<i>Unique HLA alleles</i>						
THC	17	33	NA	27	14	12
JPDSC	23	50	19	34	NA	18
Narcolepsy with cataplexy	NA	29	NA	20	13	15
HIBAG Asian	43	72	34	49	19	29
HIBAG Multi-ethnic	83	142	49	79	27	49

Abbreviations: HLA, human leukocyte antigen; JPDSC, Japan PGx Data Science Consortium; THC, Tokyo Healthy Control.

Japanese narcolepsy with cataplexy

Japanese narcolepsy with cataplexy samples were obtained by the Neuropsychiatric Research Institute of Japan. As part of the diagnosis criteria, the *HLA-B*, *HLA-DQB1* and *HLA-DPB1* loci in each sample were typed at four-digit resolution; in addition, the *HLA-DRB1* locus in a subset of samples was typed based on complete linkage between *HLA-DRB1*15:01* and *HLA-DQB1*06:02*. Almost all Japanese narcolepsy with cataplexy patients have been reported to carry this particular risk haplotype.^{13,14} In the data set we used, all Japanese narcolepsy with cataplexy samples carried the *HLA-DRB1*15:01*–*HLA-DQB1*06:02* haplotype.

Data for SNP markers within the extended MHC regions were extracted from data generated with the Affymetrix 6.0 platform; after quality control (minor allele frequency < 0.05, call rate < 99%, Hardy–Weinberg equilibrium < 0.0001), 1327 candidate marker SNPs could be used for *HLA* imputation.

HIBAG references

To assess the reference sets available in HIBAG R for four-digit *HLA* imputation accuracy with Japanese samples, the published Asian ancestry or multi-ethnicity parameters estimates were used as references and THC or JPDSC data were used for validation. All published parameter estimates are based on SNP markers with call rates > 90%. All HIBAG reference *HLA* genotypes were determined by sequence-based typing, sequence-specific oligonucleotides, sequence-specific primer methods or some combination thereof.⁹ Genotyping platform-specific parameter estimates were used for *HLA* imputation on the respective genotyping platform; additional information on these platforms and data sets are available at www.biostat.washington.edu/~bsweir/HIBAG/.

Custom Japanese population-specific parameter estimates

Japanese population-specific parameter estimates were generated based on THC and JPDSC data sets to assess the effect of sample sizes (Table 1) on overall *HLA* imputation accuracy. *HLA* imputation accuracy assessments were carried out in following two stages (Figure 1): (1) each data set (THC or JPDSC) was divided randomly into two equal subsets, a training and a validation data set; the result from each training data set served as references for imputation with the respective validation set; and (2) cross-




Figure 1. Schematic workflow for evaluation of the HIBAG R package.

validation using THC/JPDS data sets in which each data set (THC or JPDS) as a whole will be used as a training data sets served as reference for imputation with the other validation data set (THC or JPDS), and the analysis is repeat in a *vice versa* manner.

Imputation parameters

SNPs within the 500 kb flanking regions were used during the SNPs selection process.

HIBAG uses the attribute bagging method for building ensemble classifier. The ensemble classifier parameter was set as 100 bootstrap samples as recommended by the HIBAG author.⁹

Imputation accuracy assessment in a disease group

SNP variants in disease groups deviate from Hardy–Weinberg equilibrium owing to inflation of risk alleles. Parameter estimates based on THC or JPDS data were used to assess four-digit HLA imputation accuracy for the Japanese narcolepsy with cataplexy data set in which a specific risk haplotype (*HLA-DRB1*15:01 -HLA-DQB1*06:02*) is carried by almost every patient represented in the data set.¹³

RESULTS

The performance of published HIBAG parameters (Asian or multi-ethnic) was evaluated by imputing HLA alleles with two data sets (THC or JPDS), each comprising healthy Japanese individuals. These same data sets, THC and JPDS, which differed in sample size, were used to generate custom Japanese-specific parameter estimates. Performances of individual custom Japanese classifiers were evaluated (1) via internal validation in which each data set was divided randomly into training and validation subsets. To assess imputation accuracy, each training data set was used as reference to impute HLA alleles within the respective validation data set and (2) via cross-validation in which each independent data set (THC or JPDS) was used as the training data set and the other data set was used, in turn, as the validation data set; imputed HLA genotypes were then compared with experimentally determined HLA genotypes. Four-digit HLA imputation performance was mainly represented as prediction accuracy,

which was defined as the number of correctly imputed HLA alleles over the total number of imputed HLA alleles. Quality control (call threshold; CT) was applied at CT=0 or CT=0.5 as recommended by HIBAG⁹ to remove poorly imputed HLA alleles. In addition, a series of CTs was applied to determine the optimum CT for the individual Japanese classifiers while taking accuracy and call rates into consideration. HLA imputation performance for each HLA allele was evaluated based on sensitivity, specificity, positive prediction value and negative prediction value (Supplementary Tables 1–8).

Evaluation of published parameters using THC and JPDS data sets

Published, genotyping platform-specific parameter estimates, HIBAG Asian ancestry or HIBAG multi-ethnicity, were used as references to impute four-digit HLA genotypes from THC and JPDS data sets; the imputed genotypes were then compared with experimentally determined HLA genotypes.

THC data generated with three SNP genotyping platforms were used for HLA imputation; the number of SNP markers useful for imputation ranged from 219 to 321 with Affymetrix 6.0, 435 to 805 with Affymetrix Axiom and 573 to 986 with Illumina HumanOmni 2.5 (Table 2). The number of SNP markers used for each classifier depended on the density of SNP markers in the respective genotyping platform; notably, Illumina HumanOmni 2.5 had the highest density of SNP markers in the MHC region among the three platforms. When HIBAG Asian parameters were used as references, four-digit HLA imputation accuracies ranged from 90–96.9% with Affymetrix 6.0, 91.1–98.6% with Affymetrix Axiom and 91.4–98.7% with Illumina HumanOmni 2.5. Among the five HLA loci imputed, HLA-B alleles were consistently imputed with lowest accuracy with data from each genotyping platform; accuracies were 90.5, 91.1 and 91.4% with Affymetrix 6.0, Affymetrix Axiom or Illumina HumanOmni 2.5, respectively (Table 2). When HIBAG multi-ethnic parameters were used, four-digit HLA imputation accuracies decreased slightly to 82.5–96.7% with Affymetrix 6.0, 88.6–98.4% with Affymetrix Axiom and 88.9–98.8% with Illumina

Table 2. Summary of two-field prediction accuracies (call rates) based on published HIBAG Asian or HIBAG multi-ethnic parameters as references when THC data were used as the independent Japanese validation set

	HLA type				
	A	B	DRB1	DQB1	DPB1
<i>HIBAG Asian</i>					
<i>Affymetrix 6.0</i>					
No. of SNPs	319	321	256	276	226
No. of training samples	606	713	696	612	527
No. of missing SNPs (%)	80 (25.1)	74 (23.1)	61 (23.8)	66 (23.9)	56 (24.8)
Accuracy (call rate)	91.3 (100)	90.5 (100)	91.7 (100)	96.7 (100)	96.9 (100)
<i>Affymetrix Axiom</i>					
No. of SNPs	710	531	714	805	526
No. of training samples	606	713	696	612	527
No. of missing SNPs (%)	162 (22.8)	105 (19.8)	144 (20.2)	152 (18.9)	109 (20.7)
Accuracy (call rate)	93.4 (100)	91.1 (100)	92.2 (100)	98.6 (100)	96.8 (100)
<i>Illumina HumanOmni 2.5</i>					
No. of SNPs	983	986	922	1041	707
No. of training samples	606	713	696	612	527
No. of missing SNPs (%)	176 (17.9)	200 (20.3)	176 (19.1)	178 (17.1)	169 (23.9)
Accuracy (call rate)	93.3 (100)	91.4 (100)	96.2 (100)	98.7 (100)	92.3 (100)
<i>HIBAG multi-ethnic</i>					
<i>Affymetrix 6.0</i>					
No. of SNPs	297	293	219	249	207
No. of training samples	2901	3886	3713	2985	2489
No. of missing SNPs (%)	84 (28.3)	69 (23.5)	60 (27.4)	67 (26.9)	56 (27.1)
Accuracy (call rate)	89.8 (100)	88.9 (100)	82.5 (100)	92.5 (100)	96.7 (100)
<i>Affymetrix Axiom</i>					
No. of SNPs	649	489	631	692	435
No. of training samples	2901	3886	3713	2985	2489
No. of missing SNPs (%)	154 (23.7)	100 (20.4)	136 (21.6)	138 (19.9)	99 (22.8)
Accuracy (call rate)	93.3 (100)	90.0 (100)	88.6 (100)	98.4 (100)	96.4 (100)
<i>Illumina HumanOmni 2.5</i>					
No. of SNPs	910	915	861	906	573
No. of training samples	2901	3886	3713	2985	2489
No. of missing SNPs (%)	178 (19.6)	179 (19.6)	186 (21.6)	178 (19.6)	166 (29.0)
Accuracy (call rate)	93.2 (100)	90.1 (100)	88.9 (100)	98.8 (100)	97.3 (100)

Abbreviation: SNP, single nucleotide polymorphism.

HumanOmni 2.5, and imputation accuracies were highest for *HLA-DPB1* and *HLA-DQB1*. In general, *HLA* imputation with HIBAG references yielded imputation accuracies >90%, and imputation accuracy was generally higher with HIBAG Asian references than with HIBAG multi-ethnicity references.

Using a bigger Japanese control data set (JPDSC) genotyped by Illumina HumanOmni 2.5, the number of SNPs used for imputation at five *HLA* genes ranged from 260 to 347 for published HIBAG Asian ancestry parameters and 573 to 945 for HIBAG multi-ethnicity published parameters (Table 3). Imputation accuracies ranged from 91.9 to 96.6% using published HIBAG Asian ancestry parameters and from 88.5 to 97.0% using published HIBAG multi-ethnicity parameters. Imputation accuracies were highest for *HLA-C* and *HLA-DPB1* with the HIBAG Asian or HIBAG multi-ethnicity parameters, respectively. With both HIBAG reference sets, imputation accuracy was lowest for *HLA-DRB1*. The findings were similar to those for the THC validation data set (Table 2); *HLA* imputation with the JPDSC data set indicated that the HIBAG Asian references outperformed HIBAG multi-ethnicity references for Japanese populations.

Internal validation of imputation accuracy with the THC and JPDSC data sets. Internal validation tests were performed to evaluate the performance of our custom Japanese-based individual

classifiers. For each data set, all samples were divided into equal-sized subsets, a training and a validation data set. This random partitioning strategy is one of the functions of HIBAG software in which approximately equal numbers of individuals who carried specific *HLA* alleles are divided into training and validation data sets.

For THC data without any CT, imputation accuracies observed in the internal validation ranged from 93.0 to 98.3%, 91.7 to 98.3% and 92.2 to 98.3% with Affymetrix 6.0, Affymetrix Axiom or Illumina HumanOmni 2.5 data, respectively. Imputation accuracies increased to 95.3–99.0% (Affymetrix 6.0), 95.1–98.3% (Affymetrix Axiom) and 95.2–99.5% (Illumina HumanOmni 2.5) after applying a CT of 0.5, but call rates were reduced to 84.9–96.6% (Affymetrix 6.0), 88.4–100% (Affymetrix Axiom) or 85.4–97.1% (Illumina HumanOmni 2.5) (Table 4). *HLA-B* was consistently imputed with the lowest accuracy across the three genotyping platforms, probably because rare *HLA-B* alleles were underrepresented in the relatively low number of samples in the THC group. Results for *HLA* imputation accuracy for each specific *HLA* allele before application of CT are available in Supplementary Tables 1 and after CT application in Supplementary Tables 6–8.

With the JPDSC data set, the internal validation test yielded high imputation accuracy ranges: 95.7–98.9% (CT=0) or 96.7–99.0% (CT=0.5). The call rates fell within the acceptable range of

Table 3. Summary of two-field prediction accuracies (call rate) based on published HIBAG Asian or HIBAG multi-ethnic parameters as references when JPDS data were used as the independent Japanese validation set

	HLA type				
	A	B	C	DRB1	DPB1
<i>HIBAG Asian</i>					
<i>Illumina HumanOmni 2.5</i>					
No. of SNPs	260	336	347	319	273
No. of training samples	606	713	611	696	527
No. of missing SNPs (%)	40 (15.4)	55 (16.4)	55 (15.9)	51 (16.0)	46 (16.8)
Accuracy (call rate)	92.8 (100)	92.2 (100)	96.6 (100)	91.9 (100)	96.1 (100)
<i>HIBAG multi-ethnic</i>					
<i>Illumina HumanOmni 2.5</i>					
No. of SNPs	910	915	945	861	573
No. of training samples	2901	3886	2916	3713	2489
No. of missing SNPs (%)	186 (20.4)	198 (21.6)	208 (22.0)	188 (21.8)	158 (27.6)
Accuracy (call rate)	92.0 (100)	92.0 (100)	96.5 (100)	88.5 (100)	97.0 (100)

Abbreviation: SNP, single nucleotide polymorphism.

Table 4. Accuracies of two-field HLA predictions in internal validation test with THC or JPDS data and different genotyping platforms

	HLA type				
	A	B	DRB1	DQB1	DPB1
<i>THC</i>					
<i>Affymetrix 6.0</i>					
No. of SNPs	371	381	379	410	305
No. of training samples	212	216	213	210	210
No. of validation samples	203	199	202	205	205
Call threshold = 0	94.6 (100)	93.0 (100)	95.5 (100)	98.3 (100)	97.8 (100)
Call threshold = 0.5	95.3 (94.6)	95.9 (84.9)	97.3 (91.6)	99.0 (96.6)	98.2 (94.1)
<i>Affymetrix Axiom</i>					
No. of SNPs	1175	1044	1806	1962	1372
No. of training samples	212	218	215	212	211
No. of validation samples	204	198	201	204	205
Call threshold = 0	95.1 (100)	91.7 (100)	95.8 (100)	98.3 (100)	96.6 (100)
Call threshold = 0.5	95.5 (98.0)	95.1 (88.4)	97.9 (94.0)	98.3 (100)	97.4 (95.1)
<i>Illumina HumanOmni 2.5</i>					
No. of SNPs	1133	1437	1350	1436	1051
No. of training samples	213	219	215	213	212
No. of validation samples	205	199	203	205	206
Call threshold = 0	93.9 (100)	92.2 (100)	95.8 (100)	98.3 (100)	97.8 (100)
Call threshold = 0.5	95.2 (95.6)	95.6 (85.4)	97.6 (91.6)	99.5 (96.6)	98.2 (97.1)
<i>JPDS</i>					
<i>Illumina HumanOmni 2.5</i>					
No. of SNPs	1555	1668	1772	1778	1381
No. of training samples	1502	1513	1502	1508	1501
No. of validation samples	1492	1481	1492	1486	1493
Call threshold = 0	95.7 (100)	97.1 (100)	98.9 (100)	98.4 (100)	98.8 (100)
Call threshold = 0.5	96.7 (96.7)	97.6 (96.4)	99.0 (99.7)	98.7 (98.7)	99.0 (99.3)

Abbreviations: HLA, human leukocyte antigen; JPDS, Japan PGx Data Science Consortium; SNP, single nucleotide polymorphism; THC, Tokyo Healthy Control.

96.4–99.0% with a CT of 0.5 (Table 4). Results for HLA imputation accuracy at each specific HLA allele before CT application are available in Supplementary Tables 1 and 5, and after CT application in Supplementary Table 9.

Cross-validation test with THC and JPDS data sets

To evaluate the imputation efficiency of individual classifiers derived from THC or JPDS data, cross-validation tests were

performed in which THC individual classifiers were used as references for HLA imputation with JPDS data and vice versa (Figure 1). Only overlapping genotyping platform data (Illumina HumanOmni 2.5) and overlapping HLA loci (HLA-A, HLA-B, HLA-DRB1, HLA-DPB1) were used for the cross-validation test. Using THC individual classifiers as reference to impute HLA genotypes from the JPDS validation data set, we achieved imputation accuracies of 93.5–97.8% across four HLA loci. After applying CT=0.5, accuracies increased to 94.7–98.2% with call rates of

Table 5. Summary of accuracies for two-field HLA predictions from cross-validation tests with the THC and JPDSC data sets

	HLA type			
	A	B	DRB1	DPB1
<i>Illumina HumanOmni 2.5</i>				
<i>Training = THC, validation = JPDSC</i>				
No. of SNPs	1133	1437	1350	1051
No. of training samples	418	418	418	418
No. of missing SNPs (%)	35 (3.1)	58 (4.0)	19 (1.4)	28 (2.7)
Call threshold = 0	93.5 (100)	95.5 (100)	96.8 (100)	97.8 (100)
Call threshold = 0.5	94.7 (94.8)	97.4 (92.6)	98.0 (95.0)	98.2 (98.2)
<i>Training = JPDSC, validation = THC</i>				
No. of SNPs	1623	1750	1807	1301
No. of training samples	2994	2994	2994	2994
No. of missing SNPs (%)	733 (45.2)	639 (36.5)	868 (48.0)	590 (45.3)
Call threshold = 0	95.3 (100)	96.9 (100)	98.1 (100)	98.7 (100)
Call threshold = 0.5	96.2 (96.7)	97.5 (95.7)	99.1 (96.7)	98.8 (99.5)

Abbreviations: HLA, human leukocyte antigen; JPDSC, Japan PGx Data Science Consortium; SNP, single nucleotide polymorphism; THC, Tokyo Healthy Control.

Table 6. Summary of accuracies for two-field HLA predictions for the Japanese narcolepsy with cataplexy data set based on THC references

	HLA type			
	B	DRB1	DQB1	DPB1
<i>Affymetrix 6.0</i>				
No. of SNPs	381	379	410	305
No. of training samples	418	418	418	418
No. of validation samples	398	86 ^a	398	398
Call threshold = 0	94.5 (100)	92.4 (100)	98.6 (100)	97.2 (100)
Call threshold = 0.5	97.0 (79.1)	95.1 (83.7)	99.6 (69.6)	97.7 (97.7)

^aOnly 86 individuals are typed at HLA-DRB1.

92.6–98.2% (Table 5). Prediction accuracies for HLA-DPB1 were the highest and were closely followed by those for HLA-DRB1, HLA-B and HLA-A. When JPDSC individual classifiers were used as references for imputation with THC data, accuracies were from 95.3 to 98.7%, and accuracies were higher, 96.2–99.1%, after quality control (CT = 0.5) with call rates of 95.7–99.5%. Prediction accuracies for HLA-DPB1 and HLA-DRB1 were highest and closely followed by those for HLA-B and HLA-A.

Evaluation of mis-imputed HLA alleles

Four-digit HLA allele imputation accuracies and most likely mis-imputed alleles are shown in Supplementary Table 1. For example, among the HLA-A alleles, HLA-A*01:01, 03:01, 03:02, 31:01 and 33:03 were consistently imputed correctly with all five reference sets. When any one of these alleles was mis-imputed, in most cases, it was imputed correctly to the one-field resolution, for example, when HLA-A*02:01 was mis-imputed, it was always mis-imputed as HLA-A*02:07. This mis-imputed trend was observed in all the six HLA genes we tested (Supplementary Table 1). The consistent pattern of mis-imputation showed the limitation of HLA imputation most likely owing to insufficient samples size at those particular HLA alleles; however, users can refer to Supplementary Table 1 to ascertain the reliability of the imputation accuracy for a particular HLA allele.

CT evaluation

Imputed HLA alleles were filtered by posterior probability (CT) to eliminate poorly imputed HLA alleles. HIBAG instructional

materials recommend a CT of 0.5 to remove poorly imputed HLA alleles.⁹ In using THC data that were genotyped with three different genotyping platforms, we sought to determine the optimal CT for individual Japanese classifiers. Our results (Supplementary Figure 1) showed that a CT of 0.5 was too stringent when compared with a CT of 0.4; accuracy increased only marginally, ~1%, and call rates were reduced by up to ~8%; increasing the CT from 0.4 to 0.5 resulted in a loss of statistical power for identifying associated HLA alleles. We suggested applying a CT of 0.4 when reference data were generated from a relatively homogeneous population, such as a Japanese population.¹⁵

HLA imputation test with an independent disease group: Japanese patients presenting narcolepsy with cataplexy

Disease groups are known to have distorted linkage disequilibrium structures relative to normal populations; therefore, we tested the robustness of our custom THC Affymetrix 6.0 individual classifiers, with the Japanese patients presenting narcolepsy with cataplexy disease group. A specific HLA haplotype, HLA-DRB1*15:01 -HLA-DQB1*06:02, is carried by all Japanese patients who present narcolepsy with cataplexy in our data set; therefore, this haplotype is an important supplementary diagnostic indicator for diagnosis of these patients.^{13,14} We evaluated the four-digit HLA imputation accuracy with THC references for the available narcolepsy with cataplexy HLA data (HLA-B, HLA-DRB1, HLA-DQB1 and HLA-DPB1). Without any quality control (CT = 0), the most accurately imputed HLA locus was HLA-DQB1 (98.6%), followed by HLA-DPB1 (97.2%), HLA-B (94.5%) and HLA-DRB1 (92.4%) (Table 6).

With quality control (CT = 0.5), imputation accuracies increased for *HLA-DQB1* (99.6%), *HLA-DPB1* (97.7%), *HLA-B* (97.0%) and *HLA-DRB1* (95.1%); with quality control, call rates decreased and ranged from 69.6 to 97.7% (Table 6). Notably, with our THC references, the *HLA-DQB1*06:02* allele was detected with 99.7% accuracy (1 error in 398 samples tested); moreover, *HLA-DRB1*15:01* was imputed with 100% accuracy in 86 samples tested, and the remaining 312 samples were imputed as *HLA-DRB1*15:01* positive consistent with the *HLA* profiles of Japanese narcolepsy with cataplexy.^{13,14}

DISCUSSION

The HIBAG R package,⁹ together with the published parameter estimates, is freely available to the public. The parameter estimates file only contains information regarding haplotype frequencies with different SNP subsets for imputation. The absence of individual SNP/*HLA* information in the parameter estimates file encourages the sharing of parameter estimates between researchers without worry of leakage of personally identifiable information. The HIBAG website (www.biostat.washington.edu/~bsweir/HIBAG/) is equipped with an array of parameter estimates, representing the major commercial genotyping platforms stratified by population.

Here, we examine the practicality of using the published parameter estimates with data from a homogeneous population, specifically Japanese populations. We utilized two Japanese healthy control samples sets with different sample sizes to access the imputation accuracy using genotype platform-specific reference in both HIBAG Asian reference and HIBAG multi-ethnic reference. For THC data sets, imputation accuracies ranged from 90.5 to 98.7% with HIBAG Asian references and 82.5 to 98.8% with HIBAG multi-ethnicity references. For the JPDSC data set, imputation accuracies ranged from 91.9 to 96.6% with HIBAG Asian references and 88.5 to 97.0% with HIBAG multi-ethnicity references. In general, HIBAG Asian references outperformed HIBAG multi-ethnicity references with the THC and JPDSC data because of the high representation of rare Asian-specific *HLA* alleles within the HIBAG Asian reference set in contrast to those of multi population reference set. *HLA-DPB1* was a notable exception because the HIBAG multi-ethnic references outperformed the HIBAG Asian references with both the THC and JPDSC data sets at this locus; *HLA-DPB1* is relatively less polymorphic than other *HLA* loci; therefore, the larger number of individuals represented in the multi-ethnicity reference set could increase detection sensitivity for many *HLA-DPB1* alleles without sacrificing detection accuracy.

With the built-in function of the HIBAG R package, we used THC and JPDSC data sets to build custom Japanese-based individual classifiers. Using an internal validation method, *HLA* imputation accuracies of 95.2–99.5% resulted from the THC individual classifiers, and accuracies of 96.7–99.0% resulted from the JPDSC individual classifiers; each accuracy range represented a marked increase from those of the HIBAG Asian or HIBAG multi-ethnicity references. Notably, the JPDSC individual classifiers outperformed the THC individual classifiers mainly because the larger sample size of JPDSC improved the representation of rare *HLA* alleles. HIBAG⁹ reported that 10 copies of an allele in the training data set is essential for high imputation sensitivity;⁹ this requirement may explain the higher accuracy and call rate for the JPDSC data sets. Cross-validation tests showed that near perfect accuracy (99.1%) could be reached for *HLA-DRB1* with JPDSC references, imputation accuracies were >96% each for *HLA-A*, *HLA-B* and *HLA-DPB1* alleles.

Unlike other *HLA* imputation software, HIBAG uses a variable selection method in which more important/representative SNP markers tend to be used more frequently. And conversely, HIBAG uses SNP markers with lower importance values less frequently, and these markers do not tend to contribute to the accuracy.⁹ Owing to different quality controls applied by users to

genome-wide association study data before *HLA* imputation, it may be impossible to match a portion of the reliable SNP markers to reference SNPs. Our results showed that, even with a missing-SNP rate as high as 48%, HIBAG predictions were still robust enough to provide imputation accuracies up to 98.1% before CT application and up to 99.1% after applying a CT of 0.5 with only a minor decrease in call rate to 96.7% (Table 5). This result was consistent with previous findings with HIBAG, specifically that missing-SNP rates up to 50% are tolerable.⁹ In general, a higher density of SNP markers in a *MHC* region resulted in a higher number of SNP markers being incorporated into an individual classifier, which, in turn, led to more robust predictions in cases of missing SNPs.

Using THC individual classifiers, we successfully imputed risk *HLA* alleles for narcolepsy with cataplexy with a near perfect accuracy of 99.7% for *HLA-DQB1*06:02* and 100% accuracy for *HLA-DRB1*15:02*. This result indicated that our individual classifiers were robust for detecting risk/protective *HLA* alleles within a disease group.

However, as with every computational prediction system, accuracy depended on several factors, including (1) the quality of genotype data, (2) the ambiguity of *HLA* alleles in the reference data set owing to low-resolution *HLA* typing and (3) missing SNPs resulting from quality control. Most of the *HLA* prediction system available does not work well to predict rare *HLA* alleles but mainly these *HLA* alleles will be imputed with low posterior probability and would only decrease the call rate of the imputed data and do not increase in false positive of the result.

In summary, although HIBAG is a robust *HLA* allele prediction system with published parameter estimates that can be used freely by the public, we suggest that custom ensemble classifiers can be built for homogeneous populations, and that sufficient sample sizes are used to build these custom classifiers to achieve higher accuracies of *HLA* allele imputation. Our individual classifiers built with THC or JPDSC data covered >99% (*HLA-A*: 99.78%, *HLA-C*: 99.90%, *HLA-B*: 99.80%, *HLA-DRB1*: 99.91% and *HLA-DPB1*: 99.93%) of the *HLA* distribution in the Japanese database (www.hla.or.jp), which represents >20 000 Japanese individuals. Our results showed that a CT of 0.4 was sufficient to eliminate poorly imputed *HLA* alleles. The imputed results should be used as a preliminary screening for existing genome-wide association study data sets, and putative associations should be confirmed via subsequent experiments.

Resources

Japanese individual classifiers would be available on request.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

This study was supported by Grants-in-Aid for Scientific Research on Innovative Areas (22133008, KT) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

REFERENCES

- Barreiro LB, Quintana-Murci L. From evolutionary genetics to human immunology: how selection shapes host defence genes. *Nat Rev Genet* 2010; **11**: 17–30.
- Robinson J, Halliwell JA, McWilliam H, Lopez R, Parham P, Marsh SG. The IMGT/HLA database. *Nucleic Acids Res* 2013; **41**: D1222–D1227.
- de Bakker PI, McVean G, Sabeti PC, Miretti MM, Green T, Marchini J et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. *Nat Genet* 2006; **38**: 1166–1172.

- 4 Evseeva I, Nicodemus KK, Bonilla C, Tonks S, Bodmer WF. Linkage disequilibrium and age of HLA region SNPs in relation to classic HLA gene alleles within Europe. *Eur J Hum Genet* 2010; **18**: 924–932.
- 5 Leslie S, Donnelly P, McVean G. A statistical method for predicting classical HLA alleles from SNP data. *Am J Hum Genet* 2008; **82**: 48–56.
- 6 Dilthey AT, Moutsianas L, Leslie S, McVean G. HLA*IMP—an integrated framework for imputing classical HLA alleles from SNP genotypes. *Bioinformatics* 2011; **27**: 968–972.
- 7 Dilthey A, Leslie S, Moutsianas L, Shen J, Cox C, Nelson MR *et al*. Multi-population classical HLA type imputation. *PLoS Comput Biol* 2013; **9**: e1002877.
- 8 Jia X, Han B, Onengut-Gumuscu S, Chen WM, Concannon PJ, Rich SS *et al*. Imputing amino acid polymorphisms in human leukocyte antigens. *PLoS One* 2013; **8**: e64683.
- 9 Zheng X, Shen J, Cox C, Wakefield JC, Ehm MG, Nelson MR *et al*. HIBAG-HLA genotype imputation with attribute bagging. *Pharmacogenomics J* 2013; **14**: 192–200.
- 10 RG-O Robert Brylla, Francis Quek. Attribute bagging: improving accuracy of classifier ensembles by using random feature subsets. *Pattern Recogn* 2003; **36**: 1291–1302.
- 11 Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM *et al*. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome. *Nat Genet* 2013; **45**: 1284–1292.
- 12 Andreassen OA, Harbo HF, Wang Y, Thompson WK, Schork AJ, Mattingsdal M *et al*. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. *Mol Psychiatry* 2014.
- 13 Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. *Tissue Antigens* 1984; **24**: 316–319.
- 14 Mignot E, Lin L, Rogers W, Honda Y, Qiu X, Lin X *et al*. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. *Am J Hum Genet* 2001; **68**: 686–699.
- 15 Paschou P, Ziv E, Burchard EG, Choudhry S, Rodriguez-Cintron W, Mahoney MW *et al*. PCA-correlated SNPs for structure identification in worldwide human populations. *PLoS Genet* 2007; **3**: 1672–1686.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>

Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website (<http://www.nature.com/tpj>).

